Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THALASSA: Deferasirox in non–transfusion‑dependent thalassemia with iron overload
2007-007000-15Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of deferasirox in iron overload and Thalassaemia (3 arms), sponsored by Novartis. Primary endpoints: Change in liver iron concentration at 1 year vs placebo and Change in liver iron concentration at 6 months vs placebo. Started Jul 2008; status: completed.
02
Drugs
deferasirox
03
Conditions
iron overloadThalassaemia
Beyond the preview
Go deeper on 2007-007000-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007000-15.